Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.
Armstrong AJ, Clarke N, Oya M, Procopio G, de Menezes J, Guedes JD, Ghatalia P, Nolè F, Din O, Spiegelhalder P, Mincik I, van Alphen R, Lumen N, Hosius C, Zhou D, Barker L, Dujka M, Saad F. Armstrong AJ, et al. Among authors: clarke n. Eur Urol Oncol. 2023 Oct 27:S2588-9311(23)00218-3. doi: 10.1016/j.euo.2023.10.004. Online ahead of print. Eur Urol Oncol. 2023. PMID: 39492050 Free article.
Are caffeine effects equivalent between different modes of administration: the acute effects of 3 mg.kg-1 caffeine on the muscular strength and power of male university Rugby Union players.
Tallis J, Duncan MJ, Clarke ND, Morris RO, Tamilio RA. Tallis J, et al. Among authors: clarke nd. J Int Soc Sports Nutr. 2024 Dec;21(1):2419385. doi: 10.1080/15502783.2024.2419385. Epub 2024 Oct 22. J Int Soc Sports Nutr. 2024. PMID: 39439175 Free PMC article. Clinical Trial.
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, S… See abstract for full author list ➔ Gillessen S, et al. Among authors: clarke n. Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024.09.017. Online ahead of print. Eur Urol. 2024. PMID: 39394013 Free article.
Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.
Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Clarke NW, et al. Eur Urol Oncol. 2024 Oct 8:S2588-9311(24)00222-0. doi: 10.1016/j.euo.2024.09.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39384451 Free article.
1,453 results